Wegovy's launch in Thaliand comes nearly a month after Eli Lilly launched its obesity management drug Mounjaro in India at ...

Novo Nordisk (NVO) has launched its weight-loss drug Wegovy in Thailand, Reuters reported on Monday, citing an executive of ...

Novo Nordisk has launched its popular weight-loss drug Wegovy in Thailand, marking its first entry into the Southeast Asian ...

Novo Nordisk has launched its hugely popular weight-loss drug Wegovy in Thailand, an executive of the Danish drugmaker's ...

Sweden's Biotage said on Tuesday that KKR had made a cash offer for the Swedish biotechnology firm, valuing it at around 11.6 ...

US stocks are set to bounce back from Monday’s losses as investors nervously weighed up progress on trade talks with India ...

Novo Nordisk (NVO) has become aware of several hundred units of Ozempic injection 1 mg distributed outside the Novo Nordisk authorized supply chain in the U.S., the company announced. The Food and ...

In this article, we are going to take a look at where Novo Nordisk A/S (NYSE:NVO) stands against other best pharma stocks to buy for long term growth. With big American pharmaceutical corporations ...

It might seem odd to group Eli Lilly and Novo Nordisk, but these drugmakers have much in common. They've been the leaders in the diabetes drug market for decades, and both are now pioneering the ...

In this exclusive interview, Business Today speaks with Vikrant Shrotriya, Managing Director of Novo Nordisk India, about the significance of semaglutide (the active ingredient in Wegovy), its ...

Novo Nordisk is preparing to launch its blockbuster obesity drug Wegovy (injectable semaglutide) in India later this year, the company told Business Today, setting the stage for a high-stakes ...

As a pioneer in diabetes care, Novo Nordisk NVO claims 34% of the USD 80 billion-plus diabetes treatment market and roughly half of the insulin market, itself worth more than USD 15 billion.